Jiménez AI - Search Results

1

Silencing human genetic diseases with oligonucleotide-based therapies.

Martínez T, Wright N, López-Fraga M, Jiménez AI, Pañeda C. Martínez T, et al. Among authors: jimenez ai. Hum Genet. 2013 May;132(5):481-93. doi: 10.1007/s00439-013-1288-1. Epub 2013 Mar 14. Hum Genet. 2013. PMID: 23494242 Review.

2

RNA interference technologies and therapeutics: from basic research to products.

López-Fraga M, Martínez T, Jiménez A. López-Fraga M, et al. BioDrugs. 2009;23(5):305-32. doi: 10.2165/11318190-000000000-00000. BioDrugs. 2009. PMID: 19754220 Free PMC article. Review.

3

RNA interference-based therapeutics: new strategies to fight infectious disease.

López-Fraga M, Wright N, Jiménez A. López-Fraga M, et al. Infect Disord Drug Targets. 2008 Dec;8(4):262-73. doi: 10.2174/187152608786734223. Infect Disord Drug Targets. 2008. PMID: 19075801 Review.

4

In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma.

Martínez T, González MV, Roehl I, Wright N, Pañeda C, Jiménez AI. Martínez T, et al. Among authors: jimenez ai. Mol Ther. 2014 Jan;22(1):81-91. doi: 10.1038/mt.2013.216. Epub 2013 Sep 12. Mol Ther. 2014. PMID: 24025749 Free PMC article.

5

Short-interference RNAs: becoming medicines.

Martínez T, Jiménez AI, Pañeda C. Martínez T, et al. Among authors: jimenez ai. EXCLI J. 2015 Jun 15;14:714-46. doi: 10.17179/excli2015-297. eCollection 2015. EXCLI J. 2015. PMID: 26648823 Free PMC article.

6

siRNA Therapeutics in Ocular Diseases.

Moreno-Montañés J, Bleau AM, Martínez T, Vargas B, González MV, Jiménez AI. Moreno-Montañés J, et al. Among authors: jimenez ai. Methods Mol Biol. 2021;2282:417-442. doi: 10.1007/978-1-0716-1298-9_23. Methods Mol Biol. 2021. PMID: 33928588 Review.

7

Phase I clinical trial of SYL040012, a small interfering RNA targeting β-adrenergic receptor 2, for lowering intraocular pressure.

Moreno-Montañés J, Sádaba B, Ruz V, Gómez-Guiu A, Zarranz J, González MV, Pañeda C, Jimenez AI. Moreno-Montañés J, et al. Among authors: jimenez ai. Mol Ther. 2014 Jan;22(1):226-32. doi: 10.1038/mt.2013.217. Epub 2013 Sep 12. Mol Ther. 2014. PMID: 24025752 Free PMC article. Clinical Trial.

8

Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease.

Benitez-Del-Castillo JM, Moreno-Montañés J, Jiménez-Alfaro I, Muñoz-Negrete FJ, Turman K, Palumaa K, Sádaba B, González MV, Ruz V, Vargas B, Pañeda C, Martínez T, Bleau AM, Jimenez AI. Benitez-Del-Castillo JM, et al. Among authors: jimenez ai, jimenez alfaro i. Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6447-6454. doi: 10.1167/iovs.16-20303. Invest Ophthalmol Vis Sci. 2016. PMID: 27893109 Free article. Clinical Trial.

9

Differential expression and localization of transient receptor potential vanilloid 1 in rabbit and human eyes.

Martínez-García MC, Martínez T, Pañeda C, Gallego P, Jimenez AI, Merayo J. Martínez-García MC, et al. Among authors: jimenez ai. Histol Histopathol. 2013 Nov;28(11):1507-16. doi: 10.14670/HH-28.1507. Epub 2013 May 27. Histol Histopathol. 2013. PMID: 23709255

10

Tivanisiran, a novel siRNA for the treatment of dry eye disease.

Moreno-Montañés J, Bleau AM, Jimenez AI. Moreno-Montañés J, et al. Among authors: jimenez ai. Expert Opin Investig Drugs. 2018 Apr;27(4):421-426. doi: 10.1080/13543784.2018.1457647. Epub 2018 Mar 29. Expert Opin Investig Drugs. 2018. PMID: 29569947 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

132 results

Search Page